Scarica l'app Stockscreener
44.15
4.42%
-2.04
Dopo l'orario di chiusura:
44.00
-0.15
-0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Precedente Chiudi:
$46.19
Aprire:
$45.37
Volume 24 ore:
2.73M
Relative Volume:
1.00
Capitalizzazione di mercato:
$11.84B
Reddito:
$2.17B
Utile/perdita netta:
$521.27M
Rapporto P/E:
24.94
EPS:
1.77
Flusso di cassa netto:
$633.79M
1 W Prestazione:
+0.73%
1M Prestazione:
+4.70%
6M Prestazione:
+1.47%
1 anno Prestazione:
+27.97%
Intervallo 1D:
$43.28
$45.84
Intervallo di 1 settimana:
$41.93
$46.31
Portata 52W:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Nome
Exelixis Inc
Settore
Industria
Telefono
(650) 837-7000
Indirizzo
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Confronta EXEL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.15 | 12.38B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-11-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Ripresa | Barclays | Equal Weight |
| 2025-09-17 | Iniziato | Goldman | Buy |
| 2025-07-08 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2024-09-19 | Iniziato | UBS | Neutral |
| 2024-04-11 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-12-19 | Iniziato | BTIG Research | Buy |
| 2023-12-15 | Iniziato | Citigroup | Buy |
| 2023-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2023-08-22 | Reiterato | Oppenheimer | Outperform |
| 2023-08-08 | Iniziato | SVB Securities | Market Perform |
| 2023-07-11 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Ripresa | Piper Sandler | Overweight |
| 2023-03-09 | Iniziato | Wells Fargo | Overweight |
| 2023-01-26 | Iniziato | Credit Suisse | Outperform |
| 2022-10-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-03 | Ripresa | Jefferies | Buy |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-18 | Ripresa | Goldman | Sell |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-03-18 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | Iniziato | Goldman | Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Underweight |
| 2018-05-11 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | Needham | Buy |
| 2017-10-17 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-16 | Reiterato | SunTrust | Buy |
| 2017-09-22 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-12 | Reiterato | Needham | Buy |
| 2017-07-14 | Iniziato | SunTrust | Buy |
| 2017-03-31 | Iniziato | Needham | Buy |
| 2017-03-16 | Iniziato | Oppenheimer | Perform |
| 2017-02-28 | Downgrade | Stifel | Buy → Hold |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2016-10-10 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | Reiterato | Stifel | Buy |
Mostra tutto
Exelixis Inc Borsa (EXEL) Ultime notizie
Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans - Yahoo Finance
EXEL: HC Wainwright Raises Price Target and Maintains Buy Rating - GuruFocus
How risky is Exelixis Inc. stock nowRate Cut & Smart Swing Trading Techniques - ulpravda.ru
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study - Finviz
What is the fair value of Exelixis Inc. stock nowMarket Trend Report & Risk Controlled Daily Plans - ulpravda.ru
Is It Time To Reassess Exelixis (EXEL) After Strong Multi‑Year Share Price Gains - Yahoo Finance
What 10 Analyst Ratings Have To Say About Exelixis - Benzinga
Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48 - MarketScreener
EXEL Receives Downgrade from Morgan Stanley, Price Target Increa - GuruFocus
2 Healthcare Stocks to Buy for 2026 and Beyond - Finviz
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols - ADVFN
Exelixis stock rating downgraded by Morgan Stanley despite price target hike - Investing.com Canada
Exelixis and Natera to collaborate on MRD-guided cancer trial By Investing.com - Investing.com Nigeria
2 Healthcare Stocks to Buy for 2026 and Beyond - The Motley Fool
The Truth About Exelixis Inc: Is This Quiet Cancer Stock About To Explode? - AD HOC NEWS
Exelixis and Natera stocks rise on colorectal cancer trial collaboration By Investing.com - Investing.com South Africa
Exelixis and Natera stocks rise on colorectal cancer trial collaboration - Investing.com
Exelixis, Natera to Collaborate on Phase 3 Colorectal Cancer Trial - MarketScreener
Exelixis and Natera to collaborate on Stellar-316, a phase 3 pivotal trial of zanzalintinib - MarketScreener
Exelixis (EXEL) Collaborates on Innovative Colorectal Cancer Tri - GuruFocus
Exelixis and Natera to collaborate on MRD-guided cancer trial - Investing.com India
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer - Yahoo Finance
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 - The Joplin Globe
Dental EconomicsExelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 - FinancialContent
Exelixis cut to underperform at BofA on valuation and lack of catalysts - MSN
Exelixis (EXEL) Downgraded by Bank of America Amid Valuation Con - GuruFocus
Exelixis (EXEL) Downgraded by Bank of America Amid Valuation Concerns - GuruFocus
Exelixis Faces Limited High-Impact Catalysts, BofA Says - MarketScreener
BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43 - marketscreener.com
EXELExelixis Announces Second Quarter 2007 Financial Results and Business Update - ADVFN
Exelixis, Inc. (EXEL): Investor Outlook on a Biotech Powerhouse with a 30.56% Return on Equity - DirectorsTalk Interviews
Gains Report: Can Exelixis Inc EX9 stock sustain margin levels2025 Trading Recap & Momentum Based Trading Ideas - moha.gov.vn
Aug Sectors: Is Exelixis Inc EX9 stock cheap vs fundamentalsEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, & Marketing to Support Commercialization of Cabozan... - ADVFN
See How Rare Bullish Inflows Lift Outliers Like Exelixis - Yahoo Finance
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Trading the Move, Not the Narrative: (EXEL) Edition - Stock Traders Daily
Does Exelixis (NASDAQ:EXEL) Deserve A Spot On Your Watchlist? - Yahoo Finance
Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma - ADVFN
Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib & Abiraterone in Men With Castr... - ADVFN
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafeni... - ADVFN
Exelixis Inc Stock Analysis and ForecastLarge Cap Stability Picks & Double Or Triple Capital - earlytimes.in
Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib & Atezolizumab in Metastatic C... - ADVFN
Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metasta... - ADVFN
Exelixis Receives $150 Million Funding Commitment From Deerfield Management - ADVFN
Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration - ADVFN
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refract... - ADVFN
Exelixis Earnings Notes - Trefis
History Review: Is Exelixis Inc stock trading at a premium valuationPortfolio Return Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
Exelixis (MIC:EXEL-RM) EV-to-FCF : 0.00 (As of Dec. 26, 2025) - GuruFocus
Exelixis (HAM:EX9) EV-to-OCF : 13.21 (As of Dec. 22, 2025) - GuruFocus
Exelixis Inc Azioni (EXEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):